{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-081601","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2025-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.734459+00:00","generated_at":"2026-05-20T00:07:25.801276+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cullinan licenses BCMAxCD3 bispecific velinotamig from Genrix for $20M upfront, up to $692M milestones","bullets":["Upfront license fee of $20 million; Genrix eligible for up to $292M in development/regulatory milestones and up to $400M in sales-based milestones.","Tiered royalties on ex-Greater China net sales ranging from mid-single digit to mid-teens percent.","Velinotamig has shown potential best-in-class efficacy in ~50 relapsed/refractory multiple myeloma patients; Cullinan to develop in autoimmune diseases.","Genrix plans Phase 1 autoimmune study in China by end of 2025; Cullinan will conduct global development after that.","Cullinan reiterates cash runway into 2028 based on current operating plan."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-081601","json":"https://secwatch.observer/filing/0000950170-25-081601.json","markdown":"https://secwatch.observer/filing/0000950170-25-081601.md","text":"https://secwatch.observer/filing/0000950170-25-081601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000095017025081601/0000950170-25-081601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000095017025081601/cgem-20250604.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T00:07:25.801276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}